EIB lends VaxThera €35M to expand Colombian vaccine production
What's the deal? The European Investment Bank (EIB), working with the European CommissionDealroom has a profile for this one. Try Dealroom →, has approved a €35 million venture loan for VaxTheraDealroom has a profile for this one. Try Dealroom →, a Colombian biotech that develops and manufactures vaccines and biopharma products. A first €15 million tranche was announced in New York on the margins of the UN General Assembly.
What's the endgame? The financing will fund construction, fit-out, and validation of the second phase of VaxThera's commercial-scale manufacturing facility in Colombia. The expansion adds end-to-end vaccine production, including upstream processing and precision filling.
Why now? VaxThera has been building out its pipeline through partnerships, including a vaccine development tie-up with the Serum Institute of IndiaDealroom has a profile for this one. Try Dealroom → announced in April 2026. The new capacity gives it the infrastructure to take products to commercial scale.
The signal: At €35 million, this ranks among the largest debt deals for a Colombian health company on record, in the 91st percentile of comparable rounds. It reflects European backing for building vaccine manufacturing capacity in Latin America, reducing the region's reliance on imports.
Read more: thepharmaletter.com
Image credit: ITB495
